Table 3.
P values for the mean difference between HC and MCI and HC and AD groups at both baseline and at 18 mo for each of the stratified categories
| Stratification | All groups |
HC versus MCI |
HC versus AD |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted |
Adjusted |
Unadjusted |
Adjusted |
Unadjusted |
Adjusted |
|||||||
| Baseline | 18 mo | Baseline | 18 mo | Baseline | 18 mo | Baseline | 18 mo | Baseline | 18 mo | Baseline | 18 mo | |
| Total | 1.73E-64 | 5.80E-67 | 1.30E-35 | 1.30E-35 | 8.38E-22 | 7.28E-24 | 7.06E-21 | 8.97E-23 | 1.28E-57 | 2.31E-58 | 2.11E-48 | 9.83E-50 |
| APOE ε4 −ve | 5.53E-27 | 6.95E-30 | 6.74E-19 | 1.46E-19 | 3.96E-12 | 1.15E-14 | 4.70E-13 | 1.40E-14 | 2.56E-21 | 7.70E-23 | 1.66E-21 | 8.91E-23 |
| APOE ε4 +ve | 1.43E-32 | 8.97E-35 | 1.00E-17 | 1.65E-17 | 1.19E-10 | 6.07E-11 | 6.81E-08 | 7.84E-09 | 2.23E-32 | 2.41E-33 | 1.80E-24 | 2.72E-25 |
| Female | 3.39E-38 | 5.44E-36 | 1.39E-21 | 3.94E-20 | 1.94E-12 | 1.61E-14 | 5.40E-12 | 3.23E-14 | 6.94E-36 | 4.30E-31 | 3.10E-30 | 1.81E-26 |
| Male | 4.63E-27 | 5.26E-32 | 1.32E-15 | 1.18E-17 | 8.05E-11 | 6.03E-11 | 3.47E-10 | 7.49E-10 | 1.77E-23 | 3.65E-29 | 9.91E-20 | 6.02E-25 |
| Age | ||||||||||||
| <65 | 3.37E-08 | 0.0002 | 6.06E-06 | 0.0004 | 0.0222 | 1.0000 | 0.0441 | 1.0000 | 1.57E-08 | 8.50E-05 | 6.71E-09 | 0.0001 |
| 65–75 | 1.75E-23 | 1.75E-26 | 7.21E-16 | 1.05E-16 | 3.13E-11 | 4.97E-11 | 5.03E-12 | 1.33E-11 | 6.60E-19 | 9.09E-22 | 8.20E-18 | 8.45E-22 |
| 75–85 | 6.53E-21 | 3.48E-23 | 1.14E-13 | 1.52E-15 | 2.75E-07 | 6.26E-09 | 1.11E-05 | 7.98E-09 | 2.32E-20 | 5.44E-22 | 2.19E-16 | 7.81E-20 |
| >85 | 9.53E-07 | 2.87E-09 | 0.0001 | 4.05E-05 | 0.0005 | 1.54E-05 | 1.0000 | 0.0001 | 3.20E-07 | 3.16E-09 | 1.0000 | 5.73E-07 |
Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer's disease; APOE ε4, apolipoprotein ε4.
NOTE. A value of 1.000 represents not enough participants in the subgroup for a valid statistical test